[Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas].
Infantile hemangioma (IH) is one of the most common benign vascular tumors in children. A variety of treatment methods have been documented for the management of IH over the past years, including pharmacotherapy via oral administration or injection of corticosteroids, vincristine, alpha interferon and bleomycin; laser therapy, radionuclide therapy, cryotherapy and excisional surgery. The therapeutic efficacy of each treatment modality is variable, while adverse effects or complications are common and sometimes serious. Since the serendipitous discovery of propranolol, a nonselective beta-adrenergic receptor blocker, being very efficacious in treating IH in 2008, oral propranolol has earned a role as a first-line medical therapy for complicated IH. However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial. To standardize the use of propranolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese experts consensus on the use of oral propranolol for treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion.
Department of Oral and Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011, China. E-mail:davidzhengjw@sjtu.edu.cn.
Jia-Wei
JW
Zheng
Xu-Kai
XK
Wang
Zhong-Ping
ZP
Qin
Xin-Dong
XD
Fan
Kai
K
Li
Yao-Wu
YW
Yang
Ran
R
Huo
Shao-Hua
SH
Liu
Ji-Hong
JH
Zhao
Xiao-Yong
XY
Wang
De-Kai
DK
Zhou
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D032921:Consensus; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D053685:Laser Therapy; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D012878:Skin Neoplasms; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol